Literature DB >> 33437514

Immunomodulatory potential of anti-idiotypic antibodies for the treatment of autoimmune diseases.

Shing Yi Pan1,2,3, Yvonne Cashinn Chia2,3, Hui Rong Yee2,3, Angelina Ying Fang Cheng2,3, Clarice Evey Anjum2,3, Yenny Kenisi2,3, Mike Ks Chan1,2,3, Michelle Bf Wong1,2,3.   

Abstract

The immune system is a complex network of specialized cells and organs that recognises and reacts against foreign pathogens while remaining unresponsive to host tissues. This ability to self-tolerate is known as immunological tolerance. Autoimmune disease occurs when the immune system fails to differentiate between self and non-self antigens and releases autoantibodies to attack our own cells. Anti-idiotypic (anti-ID) antibodies are important in maintaining a balanced idiotypic regulatory network by neutralising and inhibiting the secretion of autoantibodies. Recently, anti-ID antibodies have been advanced as an alternative form of immunotherapy as they can specifically target autoantibodies, cause less toxicity and side effects, and could provide long-lasting immunity. This review article discusses the immunomodulatory potential of anti-ID antibodies for the treatment of autoimmune diseases.
© 2020 Shing Yi Pan, Yvonne Cashinn Chia, Hui Rong Yee et al.

Entities:  

Year:  2020        PMID: 33437514      PMCID: PMC7787174          DOI: 10.2144/fsoa-2020-0142

Source DB:  PubMed          Journal:  Future Sci OA        ISSN: 2056-5623


  84 in total

Review 1.  Side effects of anti-TNF therapy: current knowledge.

Authors:  C Antoni; J Braun
Journal:  Clin Exp Rheumatol       Date:  2002 Nov-Dec       Impact factor: 4.473

2.  Evidence for a role of anti-idiotypic antibodies in the induction of remission in Graves' disease.

Authors:  R Paschke; J Teuber; I Enger; R Schmeidl; U Schwedes; K H Usadel
Journal:  J Autoimmun       Date:  1990-08       Impact factor: 7.094

3.  A monoclonal anti-idiotypic antibody bearing the image of an epitope specific to the human carcinoembryonic antigen.

Authors:  F J Gaida; U Fenger; C Wagener; M Neumaier
Journal:  Int J Cancer       Date:  1992-05-28       Impact factor: 7.396

4.  Anti-idiotypic antibodies prevent the serologic detection of antiribosomal P autoantibodies in healthy adults.

Authors:  Z J Pan; C J Anderson; H A Stafford
Journal:  J Clin Invest       Date:  1998-07-01       Impact factor: 14.808

5.  Ribosomal P autoantibodies are present before SLE onset and are directed against non-C-terminal peptides.

Authors:  Latisha D Heinlen; Lauren L Ritterhouse; Micah T McClain; Michael P Keith; Barbara R Neas; John B Harley; Judith A James
Journal:  J Mol Med (Berl)       Date:  2010-04-17       Impact factor: 4.599

6.  Active specific immunotherapy in patients with melanoma. A clinical trial with mouse antiidiotypic monoclonal antibodies elicited with syngeneic anti-high-molecular-weight-melanoma-associated antigen monoclonal antibodies.

Authors:  A Mittelman; Z J Chen; T Kageshita; H Yang; M Yamada; P Baskind; N Goldberg; C Puccio; T Ahmed; Z Arlin
Journal:  J Clin Invest       Date:  1990-12       Impact factor: 14.808

7.  Colorectal cancer vaccines: antiidiotypic antibody, recombinant protein, and viral vector.

Authors:  S Basak; S Eck; R Gutzmer; A J Smith; B Birebent; E Purev; L Staib; R Somasundaram; J Zaloudik; W Li; L Jacob; E Mitchell; D Speicher; D Herlyn
Journal:  Ann N Y Acad Sci       Date:  2000-06       Impact factor: 5.691

Review 8.  Hybridoma technology a versatile method for isolation of monoclonal antibodies, its applicability across species, limitations, advancement and future perspectives.

Authors:  Hilal Ahmed Parray; Shivangi Shukla; Sweety Samal; Tripti Shrivastava; Shubbir Ahmed; Chandresh Sharma; Rajesh Kumar
Journal:  Int Immunopharmacol       Date:  2020-05-27       Impact factor: 4.932

9.  Decline in titers of anti-idiotypic antibodies specific to autoantibodies to GAD65 (GAD65Ab) precedes development of GAD65Ab and type 1 diabetes.

Authors:  Helena Elding Larsson; Ida Jönsson; Ake Lernmark; Sten Ivarsson; Jared R Radtke; Christiane S Hampe
Journal:  PLoS One       Date:  2013-06-13       Impact factor: 3.240

10.  Anti-ganglioside anti-idiotypic vaccination: more than molecular mimicry.

Authors:  Ana M H Vázquez; Nely Rodrèguez-Zhurbenko; Ana M V López
Journal:  Front Oncol       Date:  2012-11-20       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.